| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Omar K Siddiqi, Yuliya Y Mints, John L Berk, Lawreen Connors, Gheorghe Doros, Deepa M Gopal, Shivangi Kataria, Graham Lohrmann, Alexandra R Pipilas, Frederick L Ruber. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2022-01-27. PMID:35083944. |
diflunisal is a non-steroidal anti-inflammatory drug that stabilises transthyretin (ttr) and reduces neurologic deterioration in patients with polyneuropathy caused by hereditary transthyretin amyloidosis (attrv). |
2022-01-27 |
2023-08-13 |
Not clear |
| Ah Reum Han, Eun Hee Jeon, Kun Woo Kim, Seul Ki Lee, Chan-Yeong Ohn, Sung Jean Park, Nam Sook Kang, Tae-Sung Koo, Ki Bum Hong, Sungwook Cho. Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors. Bioorganic & medicinal chemistry. vol 53. 2021-12-10. PMID:34890995. |
transthyretin (ttr) is one of the more than 30 human amyloidogenic proteins involved in conditions such as senile systemic amyloidosis, familial amyloid polyneuropathy, and familial amyloid cardiomyopathy. |
2021-12-10 |
2023-08-13 |
human |
| Vanessa Cristina Cunha Sequeira, Maria Alice Penetra, Lisa Duarte, Fernanda Reis de Azevedo, Raphael Santa Rosa Sayegh, Roberto Coury Pedrosa, Márcia Waddington Cru. Hereditary transthyretin-mediated amyloidosis with polyneuropathy: baseline anthropometric, demographic and disease characteristics of patients from a reference center. Arquivos de neuro-psiquiatria. 2021-11-10. PMID:34755769. |
hereditary transthyretin-mediated (hattr) amyloidosis with polyneuropathy is a rare, inherited, multisystem, and often fatal disease caused by a variant in transthyretin (ttr) gene. |
2021-11-10 |
2023-08-13 |
Not clear |
| Haruki Koike, Takahiro Okumura, Toyoaki Murohara, Masahisa Katsun. Multidisciplinary Approaches for Transthyretin Amyloidosis. Cardiology and therapy. vol 10. issue 2. 2021-10-29. PMID:34089151. |
novel disease-modifying therapies for attr amyloidosis, such as ttr stabilizers, short interfering rna, and antisense oligonucleotides, were initially approved for attrv amyloidosis patients with polyneuropathy. |
2021-10-29 |
2023-08-13 |
Not clear |
| Cagdas Erdogan, Selma Tekin, Zeynep Unluturk, Zehra Oya Uygune. Different phenotypes of transthyretin-associated familial amyloid polyneuropathy due to a mutation in p.Glu109Gln in members of the same family. Northern clinics of Istanbul. vol 8. issue 4. 2021-09-30. PMID:34585077. |
transthyretin-associated familial amyloid polyneuropathy (ttr-fap) is an unusual but life-threatening disease that is autosomal dominant inherited and involves the mutation of the transthyretin (ttr) gene. |
2021-09-30 |
2023-08-13 |
Not clear |
| Dina Namiranian, Colin Chalk, Rami Massi. Poor Yield of Routine Transthyretin Screening in Patients with Idiopathic Neuropathy. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. vol 47. issue 6. 2021-09-29. PMID:32493526. |
transthyretin familial amyloid polyneuropathy (ttr-fap) is caused by a mutation in the transthyretin (ttr) gene. |
2021-09-29 |
2023-08-13 |
Not clear |
| Soon-Chai Low, Nor Ashikin Md Sari, Cheng-Yin Tan, Azlina Ahmad-Annuar, Kum-Thong Wong, Wan-Chung Law, Rachel Siew-Hung Sim, Kon-Ping Lin, Nortina Shahrizaila, Khean-Jin Go. Hereditary transthyretin amyloidosis in multi-ethnic Malaysians. Neuromuscular disorders : NMD. vol 31. issue 7. 2021-09-02. PMID:34059423. |
in conclusion, ttr ala97ser is the commonest mutation among ethnic chinese malaysians which presented with late-onset progressive sensorimotor polyneuropathy, autonomic dysfunction and subclinical cardiac involvement. |
2021-09-02 |
2023-08-13 |
human |
| Rosie Z Yu, Jon W Collins, Shannon Hall, Elizabeth J Ackermann, Richard S Geary, Brett P Monia, Scott P Henry, Yanfeng Wan. Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis. Nucleic acid therapeutics. vol 30. issue 3. 2021-08-19. PMID:32286934. |
a population pharmacokinetic (pk) and pharmacodynamic (pd) model was developed for inotersen to evaluate exposure-response relationships and to optimize therapeutic dosing regimen in patients with hereditary transthyretin (ttr) amyloidosis polyneuropathy (hattr-pn). |
2021-08-19 |
2023-08-13 |
human |
| Shinji Kakihara, Takao Hirano, Akira Imai, Teruyoshi Miyahara, Toshinori Murat. Baerveldt glaucoma drainage implant surgery for secondary glaucoma in patients with transthyretin-related familial amyloid polyneuropathy. Japanese journal of ophthalmology. vol 64. issue 5. 2021-08-09. PMID:32627105. |
to investigate outcomes associated with baerveldt glaucoma drainage implant (bgi) surgery for refractory glaucoma secondary to transthyretin (ttr)-related familial amyloid polyneuropathy (fap) with ttr val30met mutation. |
2021-08-09 |
2023-08-13 |
Not clear |
| Xin Jiang, Richard Labaudinière, Joel N Buxbaum, Cecília Monteiro, Marta Novais, Teresa Coelho, Jeffery W Kell. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proceedings of the National Academy of Sciences of the United States of America. vol 118. issue 9. 2021-08-09. PMID:33597308. |
to determine whether circulating nonnative ttr (nnttr) levels correlate with the clinical status of patients with v30m ttr familial amyloid polyneuropathy (fap), we quantified plasma nnttr using a newly developed sandwich enzyme-linked immunosorbent assay. |
2021-08-09 |
2023-08-13 |
human |
| T H Brannagan, A K Wang, T Coelho, M Waddington Cruz, M J Polydefkis, P J Dyck, V Plante-Bordeneuve, J L Berk, F Barroso, G Merlini, I Conceição, S G Hughes, J Kwoh, S W Jung, S Guthrie, M Pollock, M D Benson, M Gert. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. European journal of neurology. vol 27. issue 8. 2021-06-25. PMID:32343462. |
hereditary transthyretin (hattr) amyloidosis causes progressive polyneuropathy resulting from transthyretin (ttr) amyloid deposition throughout the body, including the peripheral nerves. |
2021-06-25 |
2023-08-13 |
Not clear |
| T H Brannagan, A K Wang, T Coelho, M Waddington Cruz, M J Polydefkis, P J Dyck, V Plante-Bordeneuve, J L Berk, F Barroso, G Merlini, I Conceição, S G Hughes, J Kwoh, S W Jung, S Guthrie, M Pollock, M D Benson, M Gert. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. European journal of neurology. vol 27. issue 8. 2021-06-25. PMID:32343462. |
the efficacy and safety of inotersen, an antisense oligonucleotide inhibitor of ttr protein production, were demonstrated in the pivotal neuro-ttr study in patients with hattr polyneuropathy. |
2021-06-25 |
2023-08-13 |
Not clear |
| Tatsufumi Murakami, Takeshi Yokoyama, Mineyuki Mizuguchi, Shigenobu Toné, Shizuka Takaku, Kazunori Sango, Hirotake Nishimura, Kazuhiko Watabe, Yoshihide Sunad. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy. Journal of neurochemistry. vol 156. issue 6. 2021-06-18. PMID:32852783. |
patients with transthyretin (ttr)-type familial amyloid polyneuropathy (fap) typically exhibit sensory dominant polyneuropathy and autonomic neuropathy. |
2021-06-18 |
2023-08-13 |
rat |
| Isabel Casanova, André Caetano, Andrés Díaz, Isabel Conceição, Marisa Brum, Mamede de Carvalh. Motor excitability measurements in early stage familial amyloid polyneuropathy: The influence of tafamidis treatment. Neurophysiologie clinique = Clinical neurophysiology. vol 50. issue 3. 2021-05-26. PMID:32507631. |
to test motor fiber excitability in early affected patients with transthyretin (ttr)-type familial amyloid polyneuropathy (ttr-fap) before and during tafamidis treatment. |
2021-05-26 |
2023-08-13 |
Not clear |
| Hsing-Jung Lai, Wan-Ting Lai, Lu Jin, Kuan-Ting Kuo, Ming-Jen Le. Electrophysiological parameters that contribute to the pathogenesis of familial amyloid polyneuropathy caused by transthyretin mutations. Journal of the neurological sciences. vol 413. 2021-05-14. PMID:32247966. |
familial amyloid polyneuropathy (fap) is a rare, hereditary peripheral neuropathy commonly caused by mutations in human transthyretin (ttr) gene. |
2021-05-14 |
2023-08-13 |
mouse |
| Marcia Almeida Liz, Teresa Coelho, Vittorio Bellotti, Maria Isabel Fernandez-Arias, Pablo Mallaina, Laura Obic. A Narrative Review of the Role of Transthyretin in Health and Disease. Neurology and therapy. vol 9. issue 2. 2021-03-17. PMID:33001386. |
mutations in ttr are associated with inherited transthyretin amyloidosis (attrv), a progressive, debilitating disease that is ultimately fatal and is characterized by misfolding of ttr and aggregation as amyloid fibrils, predominantly leading to cardiomyopathy or polyneuropathy depending on the particular ttr mutation. |
2021-03-17 |
2023-08-13 |
Not clear |
| Ellen Y Cotrina, Ângela Oliveira, José Pedro Leite, Jordi Llop, Luis Gales, Jordi Quintana, Isabel Cardoso, Gemma Arsequel. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer. International journal of molecular sciences. vol 21. issue 19. 2021-02-25. PMID:32998442. |
transthyretin (ttr) is a homotetrameric protein involved in human amyloidosis, including familial amyloid polyneuropathy (fap). |
2021-02-25 |
2023-08-13 |
human |
| David Adams, Michael Polydefkis, Alejandra González-Duarte, Jonas Wixner, Arnt V Kristen, Hartmut H Schmidt, John L Berk, Inés Asunción Losada López, Angela Dispenzieri, Dianna Quan, Isabel M Conceição, Michel S Slama, Julian D Gillmore, Theodoros Kyriakides, Senda Ajroud-Driss, Márcia Waddington-Cruz, Michelle M Mezei, Violaine Planté-Bordeneuve, Shahram Attarian, Elizabeth Mauricio, Thomas H Brannagan, Mitsuharu Ueda, Emre Aldinc, Jing Jing Wang, Matthew T White, John Vest, Erhan Berber, Marianne T Sweetser, Teresa Coelh. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. The Lancet. Neurology. vol 20. issue 1. 2021-01-28. PMID:33212063. |
we assessed the safety and efficacy of long-term treatment with patisiran, an rna interference therapeutic that inhibits ttr production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. |
2021-01-28 |
2023-08-13 |
Not clear |
| Marina I Oliveira da Silva, Carla S Lopes, Márcia A Li. Transthyretin interacts with actin regulators in a Drosophila model of familial amyloid polyneuropathy. Scientific reports. vol 10. issue 1. 2021-01-11. PMID:32788615. |
familial amyloid polyneuropathy (fap) is a neurodegenerative disorder whose major hallmark is the deposition of mutated transthyretin (ttr) in the form of amyloid fibrils in the peripheral nervous system (pns). |
2021-01-11 |
2023-08-13 |
drosophila_melanogaster |
| P James B Dyck, John C Kincaid, Janice F Wiesman, Michael Polydefkis, William J Litchy, Michelle L Mauermann, Elizabeth J Ackermann, Spencer Guthrie, Michael Pollock, Shiangtung W Jung, Brenda F Baker, Peter J Dyc. mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis. Muscle & nerve. vol 62. issue 4. 2020-11-27. PMID:32654212. |
inotersen, an antisense oligonucleotide inhibitor of transthyretin (ttr) protein production, demonstrated significant benefit versus placebo in the modified neuropathy impairment score (nis) +7 neurophysiologic tests (mnis+7) in patients with hereditary ttr-mediated amyloidosis (hattr) with polyneuropathy. |
2020-11-27 |
2023-08-13 |
Not clear |